Skip to main content

Drug Interactions between Cervidil and Syntocinon

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

oxytocin dinoprostone topical

Applies to: Syntocinon (oxytocin) and Cervidil (dinoprostone topical)

ADJUST DOSING INTERVAL: Prostaglandins, especially those of the E type, may potentiate the uterine response to oxytocin and increase the risk of uterine hyperstimulation and rupture. The mechanism of interaction is unknown.

MANAGEMENT: Concomitant use of oxytocin and dinoprostone is considered to be contraindicated. Infusion of oxytocin should not be started until at least 6 to 12 hours after the use of dinoprostone vaginal gel (6 to 12 hours recommended for Prepidil Gel and 12 to 24 hours for Prostin E2 Vaginal Gel) or at least 30 minutes after the removal of dinoprostone vaginal insert, or at least 1 hour after the last dose of dinoprostone oral tablet.

References

  1. "Product Information. Prepidil (dinoprostone topical)." Pharmacia and Upjohn PROD (2001):
  2. "Product Information. Prostin E2 (dinoprostone topical)." Pharmacia and Upjohn (2002):
  3. "Product Information. Cervidil (dinoprostone topical)." Forest Pharmaceuticals (2002):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer